We are live on ! Find out more
LC

Lindbrook Capital Portfolio holdings

AUM $1.08B
1-Year Est. Return 10.14%
This Fund
S&P 500
This Quarter Est. Return
+4.35%
1 Year Est. Return
+10.14%
3 Year Est. Return
+35.77%
5 Year Est. Return
+141.26%
10 Year Est. Return
AUM
$1.06B
AUM Growth
-$4.21M
Cap. Flow
-$36.2M
Cap. Flow %
-3.4%
Top 10 Hldgs %
45.51%
Holding
2,874
New
227
Increased
1,384
Reduced
630
Closed
115

Top Sells

Rank Stock Value
1
OCSL icon
Oaktree Specialty Lending
OCSL
+$12.7M
2
NVDA icon
NVIDIA
NVDA
+$6.29M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$3.66M
4
AAPL icon
Apple
AAPL
+$3.19M
5
AVGO icon
Broadcom
AVGO
+$2.17M

Sector Composition

Rank Sector Weight
1 Technology 17.21%
2 Financials 12.25%
3 Healthcare 6.29%
4 Communication Services 4.39%
5 Consumer Discretionary 3.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HTZ icon
1976
Hertz
HTZ
$756M
$5.17K ﹤0.01%
1,465
+330
+29% +$1.68K
ADT icon
1977
ADT
ADT
$5.49B
$5.17K ﹤0.01%
680
+314
+86% +$2.17K
SHOO icon
1978
Steven Madden
SHOO
$3.58B
$5.16K ﹤0.01%
122
VSXY
1979
Victoria's Secret
VSXY
$7.95B
$5.14K ﹤0.01%
291
+202
+227% +$3.84K
BXMT icon
1980
Blackstone Mortgage Trust
BXMT
$2.39B
$5.12K ﹤0.01%
294
-510
-63% -$9.21K
INVA icon
1981
Innoviva
INVA
$1.49B
$5.12K ﹤0.01%
312
+4
+1% +$62
PCOR icon
1982
Procore
PCOR
$8.84B
$5.11K ﹤0.01%
77
+54
+235% +$3.75K
NG icon
1983
NovaGold Resources
NG
$3.35B
$5.1K ﹤0.01%
1,474
+171
+13% +$567
USPH icon
1984
US Physical Therapy
USPH
$1.22B
$5.08K ﹤0.01%
55
-1
-2% -$101
CGEM icon
1985
Cullinan Oncology
CGEM
$1.18B
$5.08K ﹤0.01%
291
ADPT icon
1986
Adaptive Biotechnologies
ADPT
$4.05B
$5.05K ﹤0.01%
1,396
+634
+83% +$2.01K
MITK icon
1987
Mitek Systems
MITK
$837M
$5.05K ﹤0.01%
452
+39
+9% +$499
FRT icon
1988
Federal Realty Investment Trust
FRT
$10.2B
$5.05K ﹤0.01%
50
-10
-17% -$1.01K
EMBC icon
1989
Embecta
EMBC
$283M
$5.04K ﹤0.01%
403
-249
-38% -$3.02K
LOPE icon
1990
Grand Canyon Education
LOPE
$3.82B
$5.04K ﹤0.01%
36
+4
+13% +$551
GATX icon
1991
GATX Corp
GATX
$6.23B
$5.03K ﹤0.01%
38
+1
+3% +$132
KYMR icon
1992
Kymera Therapeutics
KYMR
$9.03B
$4.99K ﹤0.01%
167
+16
+11% +$554
SAGE
1993
DELISTED
Sage Therapeutics
SAGE
$4.99K ﹤0.01%
459
+261
+132% +$3.34K
PCRX icon
1994
Pacira BioSciences
PCRX
$974M
$4.98K ﹤0.01%
174
+30
+21% +$854
VICR icon
1995
Vicor
VICR
$9.63B
$4.97K ﹤0.01%
+150
New +$5.18K
STGW icon
1996
Stagwell
STGW
$2.22B
$4.97K ﹤0.01%
729
+298
+69% +$1.92K
EEFT icon
1997
Euronet Worldwide
EEFT
$2.65B
$4.97K ﹤0.01%
48
+2
+4% +$219
OBK icon
1998
Origin Bancorp
OBK
$1.64B
$4.95K ﹤0.01%
156
+5
+3% +$153
NCNO icon
1999
nCino
NCNO
$2.08B
$4.94K ﹤0.01%
157
+72
+85% +$2.25K
BUR icon
2000
Burford Capital
BUR
$940M
$4.92K ﹤0.01%
+377
New +$5.54K

Similar funds

Lindbrook Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Lindbrook Capital held 2,874 positions worth $1.06B, down 0.39% from $1.07B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Lindbrook Capital withdrew a net $36.2M in Q2 2024, closing 115 positions and reducing 630 holdings. Its most notable exit was ProShares UltraPro QQQ, an estimated $1.24M position sold in full.

By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 16% a quarter earlier, followed by Financials and Healthcare.

Against the trend, Lindbrook Capital opened a new position in Nuveen ESG Small-Cap ETF worth $323K.

  • Lindbrook Capital's largest Q2 2024 buy was Nuveen ESG Small-Cap ETF: 8,216 shares worth $323K.
  • Lindbrook Capital added most to State Street SPDR S&P 500 ETF Trust in Q2 2024, an estimated $3.36M increase.
  • Lindbrook Capital's biggest Q2 2024 reduction was Oaktree Specialty Lending, cutting an estimated $12.7M.
  • Lindbrook Capital fully exited ProShares UltraPro QQQ in Q2 2024, selling an estimated $1.24M.
  • Lindbrook Capital's ten largest holdings make up 46% of its $1.06B portfolio in Q2 2024.
  • Lindbrook Capital opened 227 new positions and closed 115 in Q2 2024.
  • Lindbrook Capital's portfolio value fell 0.39% quarter-over-quarter to $1.06B.

Based on Lindbrook Capital's 13F filing for Q2 2024, filed 31 Jul 2024.